Skip to main content
Cameron West, MD, Dermatology, Lubbock, TX

Cameron West MD

Dermatopathology


Dermatologist and Dermatopathologist

Join to View Full Profile
  • 3601 Fourth StStop 9400Lubbock, TX 79430

  • Phone+1 806-743-1842

Dr. West is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Texas Tech University Health Sciences Center at Lubbock
    Texas Tech University Health Sciences Center at LubbockResidency, Dermatology, 2013 - 2016
  • University of Kansas (Wichita)
    University of Kansas (Wichita)Residency, Radiology-Diagnostic, 2010 - 2011
  • University of Kansas (Wichita)
    University of Kansas (Wichita)Internship, Internal Medicine, 2009 - 2010
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 2009

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2022 - 2026
  • KS State Medical License
    KS State Medical License 2016 - 2025
  • MN State Medical License
    MN State Medical License 2016 - 2025
  • NM State Medical License
    NM State Medical License 2012 - 2013
  • NC State Medical License
    NC State Medical License 2011 - 2012
  • Dermatology
    American Board of Dermatology Dermatology
  • Dermatopathology
    American Board of Dermatology Dermatopathology
  • Dermatology
    National Board of Physicians and Surgeons Dermatology

Publications & Presentations

PubMed

Press Mentions

  • First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
    First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research InstituteMarch 20th, 2019
  • First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02
    First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02November 25th, 2018

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: